Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in QuidelOrtho Corporation, Artivion or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how QuidelOrtho Corporation, Artivion and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About QuidelOrtho Corporation, Artivion and Inc.

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Latest Health Care Equipment & Supplies and QuidelOrtho Corporation, Artivion, Inc. Stock News

As of November 21, 2025, QuidelOrtho Corporation had a $1.7 billion market capitalization, compared to the Health Care Equipment & Supplies median of $282.4 million. QuidelOrtho Corporation’s stock is down 42.9% in 2025, up 20.5% in the previous five trading days and down 36.88% in the past year.

Currently, QuidelOrtho Corporation does not have a price-earnings ratio. QuidelOrtho Corporation’s trailing 12-month revenue is $2.7 billion with a -43.5% net profit margin. Year-over-year quarterly sales growth most recently was -3.7%. Analysts expect adjusted earnings to reach $2.082 per share for the current fiscal year. QuidelOrtho Corporation does not currently pay a dividend.

As of November 21, 2025, Artivion, Inc. had a $2.1 billion market cap, putting it in the 58th percentile of all stocks. Artivion, Inc.’s stock is up 60.8% in 2025, up 1.9% in the previous five trading days and up 67.58% in the past year.

Currently, Artivion, Inc. does not have a price-earnings ratio. Artivion, Inc.’s trailing 12-month revenue is $422.6 million with a -2.2% net profit margin. Year-over-year quarterly sales growth most recently was 18.4%. Analysts expect adjusted earnings to reach $0.634 per share for the current fiscal year. Artivion, Inc. does not currently pay a dividend.

How We Compare QuidelOrtho Corporation, Artivion and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at QuidelOrtho Corporation, Artivion and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

QuidelOrtho Corporation, Artivion and Inc.’s Quality Grades

Company	Ticker	Quality
QuidelOrtho Corporation	QDEL	C
Artivion, Inc.	AORT	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

QuidelOrtho Corporation has a Quality Score of 52, which is Average. Artivion, Inc. has a Quality Score of 57, which is Average.

The Quality Stock Winner: No Clear Winner

Neither QuidelOrtho Corporation, Artivion or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if QuidelOrtho Corporation, Artivion or Inc. is the better investment when it comes to quality.

QuidelOrtho Corporation, Artivion and Inc.’s Momentum Grades

Company	Ticker	Momentum
QuidelOrtho Corporation	QDEL	F
Artivion, Inc.	AORT	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

QuidelOrtho Corporation has a Momentum Score of 19, which is Very Weak. Artivion, Inc. has a Momentum Score of 82, which is Very Strong.

The Momentum Grade Winner: Artivion, Inc.

As you can clearly see from the Momentum Grade breakdown above, Artivion, Inc. is considered to have stronger momentum compared to QuidelOrtho Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Artivion, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

QuidelOrtho Corporation, Artivion and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
QuidelOrtho Corporation	QDEL	C
Artivion, Inc.	AORT	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

QuidelOrtho Corporation has a Earnings Estimate Score of 44, which is Neutral. Artivion, Inc. has a Earnings Estimate Score of 45, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither QuidelOrtho Corporation, Artivion or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if QuidelOrtho Corporation, Artivion or Inc. is the better investment when it comes to estimate revisions.

Other QuidelOrtho Corporation, Artivion and Inc. Grades

In addition to Momentum, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether QuidelOrtho Corporation, Artivion and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, QuidelOrtho Corporation, Artivion or Inc. Stock?

Overall, QuidelOrtho Corporation stock has a Momentum Score of 19, Estimate Revisions Score of 44 and Quality Score of 52.

Artivion, Inc. stock has a Momentum Score of 82, Estimate Revisions Score of 45 and Quality Score of 57.

Comparing QuidelOrtho Corporation, Artivion and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.